Core Viewpoint - The company, Boji Pharmaceutical, is primarily focused on innovative drug development, with a diverse portfolio that includes chemical drugs, biological drugs, and traditional Chinese medicine [1] Group 1: Drug Development - The company has completed Phase III clinical trials and launched innovative drugs such as recombinant human albumin injection (from rice) and sildenafil hydrochloride tablets [1] - A self-developed traditional Chinese medicine new drug (Category 1.1) has completed Phase III clinical trials, while a collaborative development project in the same category is currently in Phase III [1] Group 2: Research and Technology - The company has established databases related to researchers, clinical trial institutions, and clinical trial projects to enhance its research capabilities [1] - The company is actively exploring the application of AI technology in drug development to improve efficiency and quality, with current usage in both preclinical and clinical operations [1]

Core Insights - The company, Boji Pharmaceutical, focuses on innovative drug development, with a diverse portfolio including chemical drugs, biological drugs, and traditional Chinese medicine [1] - The company has successfully completed Phase III clinical trials and launched innovative drugs such as recombinant human albumin injection and sildenafil citrate tablets [1] - The company is actively exploring the application of AI technology in drug development to enhance efficiency and quality, with ongoing use in both preclinical and clinical operations [1] Group 1 - The company has numerous projects in service, primarily centered on innovative drugs [1] - The company has completed Phase III clinical trials for several innovative drugs and has a traditional Chinese medicine new drug in Phase III clinical trials [1] - The company has established databases related to researchers, clinical trial institutions, and clinical trial projects [1] Group 2 - The company is transferring its self-developed projects to external clients after achieving certain technical results, allowing clients to continue development [1] - The company is exploring more applications of AI technology in drug development beyond current uses [1] - The company is preparing to establish a real-world database for AI models to enhance innovative drug clinical research [3]